Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites

NCT03697668 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Plasmodium Falciparum Malaria (Drug Resistant)

Interventions

DRUG: Imatinib
DRUG: Dihydroartemisinin-piperaquine

Sponsor

Nurex S.r.l.

Collaborators

[object Object]
[object Object]
[object Object]